Current and emerging therapies for acute myeloid leukemia

Clinical Therapeutics
Tadeusz Robak, Agnieszka Wierzbowska

Abstract

Acute myeloid leukemia (AML) is a clonal disease characterized by the proliferation and accumulation of myeloid progenitor cells in the bone marrow, which ultimately leads to hematopoietic failure. The incidence of AML increases with age, and older patients typically have worse treatment outcomes than do younger patients. This review is focused on current and emerging treatment strategies for nonpromyelocytic AML in patients aged <60 years. A literature review was conducted of the PubMed database for articles published in English. Publications from 1990 through March 2009 were scrutinized, and the search was updated on August 26, 2009. The search terms used were: acute myeloid leukemia in conjunction with treatment, chemotherapy, stem cell transplantation, and immunotherapy. Clinical trials including adults with AML aged > or =19 years were selected for analysis. Conference proceedings from the previous 5 years of The American Society of Hematology, The European Hematology Association, and The American Society for Blood and Marrow Transplantation were searched manually. Additional relevant publications were obtained by reviewing the references from the chosen articles. Cytarabine (AraC) is the cornerstone of induction therapy a...Continue Reading

References

Nov 1, 1978·Cancer·J H SaikiB Hoogstraten
Dec 28, 1999·Proceedings of the National Academy of Sciences of the United States of America·C VitaleM C Mingari
Feb 1, 2002·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Francis J GilesHagop M Kantarjian
Mar 7, 2002·Current Opinion in Oncology·Norbert-Claude Gorin
May 10, 2002·Leukemia & Lymphoma·Tadeusz Robak, Agata Wrzesień-Kuś
Jul 13, 2002·Expert Review of Anticancer Therapy·Francis J Giles
Jul 26, 2002·British Journal of Haematology·Alan K BurnettUNKNOWN Medical Research Council Adult and Paediatric Working Parties
Nov 6, 2003·Cancer·Francis GilesSusan O'Brien
Nov 25, 2003·Hematology·Bob LöwenbergMartin S Tallman
Dec 17, 2003·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·H C FungS J Forman
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter L GreenbergJacob M Rowe
Mar 17, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·John C ByrdClara D Bloomfield
May 8, 2004·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Francis GilesHagop Kantarjian
Aug 4, 2004·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·R F SchlenkG Heil
Nov 27, 2004·The New England Journal of Medicine·Vanderson RochaUNKNOWN Eurocord-Netcord Registry
Jan 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Dimitri A BreemsBob Löwenberg
May 5, 2005·Blood·Martin S TallmanJacob M Rowe

❮ Previous
Next ❯

Citations

Aug 21, 2012·Antioxidants & Redox Signaling·Mary E IrwinJoya Chandra
Aug 8, 2012·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Erin L SchenkScott H Kaufmann
Jun 9, 2012·International Journal of Nanomedicine·Donato CoscoDonatella Paolino
Dec 24, 2010·Drugs·Lily P H Yang, Caroline M Perry
Jul 9, 2013·Journal of Industrial Microbiology & Biotechnology·Jesús Fernández-LucasMiguel Arroyo
Oct 23, 2010·Expert Opinion on Drug Delivery·Bhupender S Chhikara, Keykavous Parang
Feb 16, 2011·Expert Opinion on Investigational Drugs·Tadeusz Robak
Jan 10, 2016·Applied Radiation and Isotopes : Including Data, Instrumentation and Methods for Use in Agriculture, Industry and Medicine·Catherine GaoRaymond M Reilly
Nov 16, 2010·International Journal of Cancer. Journal International Du Cancer·Mehmet Kemal TurStefan Barth
Dec 9, 2014·Cancer Biology & Therapy·Paulina WyrozumskaAleksander F Sikorski
Apr 23, 2014·BioEssays : News and Reviews in Molecular, Cellular and Developmental Biology·Mark Vincent
Sep 12, 2015·Acta Biochimica Et Biophysica Sinica·Lili SunYun Zhao
Jan 28, 2014·Asian Pacific Journal of Cancer Prevention : APJCP·Hadi KaramiEbrahim Sakhinia
Mar 19, 2014·Clinical Lymphoma, Myeloma & Leukemia·Apostolia Maria TsimberidouGautam Borthakur
Feb 4, 2014·Leukemia Research·Tadeusz Robak, Agnieszka Wierzbowska
Feb 3, 2015·Mitochondrion·Nandini Pal Basak, Subrata Banerjee
Apr 10, 2013·Cancer Treatment Reviews·Pawel Robak, Tadeusz Robak
Jul 6, 2014·Food and Chemical Toxicology : an International Journal Published for the British Industrial Biological Research Association·Chieh-Lin Jerry TengShih-Lan Hsu
Aug 14, 2010·Blood·David DornanMartin Weisser
Jan 23, 2015·Nutrition and Cancer·Itzen Aguiñiga-SánchezEdelmiro Santiago-Osorio
May 11, 2016·Protein Engineering, Design & Selection : PEDS·Hongmei RuanMargaret E Black
Dec 7, 2016·Journal of Cellular Biochemistry·Ruifang Zheng, George P Studzinski

❮ Previous
Next ❯

Related Concepts

Related Feeds

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

Allogenic & Autologous Therapies

Allogenic therapies are generated in large batches from unrelated donor tissues such as bone marrow. In contrast, autologous therapies are manufactures as a single lot from the patient being treated. Here is the latest research on allogenic and autologous therapies.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Related Papers

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
Alan BurnettBob Löwenberg
Critical Reviews in Oncology/hematology
Thomas BüchnerWolfgang Hiddemann
© 2021 Meta ULC. All rights reserved